5%+ stake

Charles River Laboratories (CRL): T. Rowe Price Associates, Inc. now owns 6.3% of CRL as a passive investor 6.3%

T. Rowe Price Associates, Inc. now owns 6.3% of CRL as a passive investor.

6.3%
Stake · was 6.3%
3.01M
Shares owned
Stake as of
Sep 30, 2026
Filed
Nov 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 28, 2026Federal contract · $5.3M obligatedDepartment of Health and Human Services awarded Charles River Laboratories: $5.31M obligated to date
  2. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
  3. Aug 5, 2026Insider · Their largest sale since 2022Officer sold ~$1.33M of CRL shares in the open market
  4. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 8.8%
  5. Aug 6, 2026Insider · 2 peopleInsiders: 10 sales (~$2.8M)
  6. Aug 10, 2026InsiderDirector sold ~$7.9M of CRL shares in the open market
  7. Aug 11, 2026Insider · 2 peopleInsiders: 2 sales (~$2.9M)
  8. Aug 13, 20265% stakeInvesco Ltd. reported a passive stake (13G) of 6.2%
  9. Aug 18, 2026Federal contract · $372K obligatedDepartment of Health and Human Services awarded Charles River Laboratories: $372K obligated to date
  10. Aug 18, 2026InsiderDirector sold ~$163K of CRL shares in the open market
  11. Aug 19, 2026InsiderOfficer sold ~$600K of CRL shares in the open market
  12. Aug 25, 2026InsiderDirector sold ~$10.1M of CRL shares in the open market
  13. Aug 31, 2026Federal contract · $1.0M obligatedDepartment of Health and Human Services awarded Charles River Laboratories: $1.01M obligated to date
  14. Sep 8, 20265% stakeFMR LLC reported a passive stake (13G) of 10.2%
  15. Sep 17, 2026Federal contract · $2.7M obligatedDepartment of Health and Human Services awarded Charles River Laboratories: $2.68M obligated to date
  16. Sep 17, 2026Federal contract · $8.2M obligatedDepartment of Health and Human Services awarded Charles River Laboratories: $8.25M obligated to date
  17. Sep 25, 2026Federal contract · $340K obligatedDepartment of Health and Human Services awarded Charles River Laboratories: $340K obligated to date

What came next

  1. Oct 5, 2026InsiderOfficer sold ~$303K of CRL shares in the open market
  2. Oct 21, 2026InsiderOfficer sold ~$743K of CRL shares in the open market
  3. Oct 22, 2026InsiderDirector sold ~$8.41M of CRL shares in the open market
  4. Nov 4, 2026Company filing · Form 8-K · ResultsReported its results
  5. Nov 5, 20265% stakeFMR LLC reported a passive stake (13G) of 12.4%
  6. Nov 10, 20265% stakeInvesco Ltd. reported a passive stake (13G) of 3.9%
  7. Nov 16, 20265% stakeT. Rowe Price Associates, Inc. reported a passive stake (13G) of 6.3%
View the official recordSEC Schedule 13G

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Charles River Laboratories

For Charles River Laboratories, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 2 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CRL page.

How this filing works

Explore the data

Common questions

What does this filing report about Charles River Laboratories (CRL) stock?

T. Rowe Price Associates, Inc. now owns 6.3% of CRL as a passive investor. Of the company, Schedule 13G (passive).

When did it happen, and when was it made public?

Stake as of: Sep 30, 2026. Filed: Nov 16, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Charles River Laboratories recently?

For Charles River Laboratories, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 2 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days. They are listed on the CRL page.

Does this mean CRL stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Charles River Laboratories

Everything OQRO holds on this company is on its CRL page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data